Skip to Main Content

Paper Details

A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus.
Sci Transl Med
212
2022
COVID-19, Molnupiravir, Participants, SARS, SARS-CoV, SARS-CoV-2, SARS-CoV-2 RNA, SARS-CoV-2 infection, Vero cells, coronavirus disease 2019, molnupiravir, nucleoside, participants, patients, reverse transcriptase, severe, severe acute respiratory syndrome, viral RNA
Author NameAffiliation
William A FischerInstitute for Global Health and Infectious Diseases, The University of North Carolina at Chapel Hill
Joseph J EronUniversity of North Carolina at Chapel Hill
Ralph S BaricUniversity of North Carolina at Chapel Hill
Ralph S BaricUniversity of North Carolina at Chapel Hill
David A WohlUniversity of North Carolina at Chapel Hill
  • 1 - 5

Datasets

Release 1.2